JP Morgan Maintains Overweight on Prime Medicine, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph has maintained an Overweight rating on Prime Medicine (NASDAQ:PRME) but has lowered the price target from $16 to $15.

May 13, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan has maintained its Overweight rating on Prime Medicine but reduced the price target from $16 to $15.
The adjustment in price target by a major analyst like JP Morgan can have a mixed impact. While maintaining an Overweight rating suggests confidence in the company's fundamentals, the reduction in price target could signal a tempered expectation for the stock's short-term performance. Investors might view this as a cautious signal, potentially leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100